Patents by Inventor MICHAEL A. MEEHL
MICHAEL A. MEEHL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220033497Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: July 16, 2021Publication date: February 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Publication number: 20220025042Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: July 16, 2021Publication date: January 27, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Publication number: 20220025043Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: July 16, 2021Publication date: January 27, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Publication number: 20220010011Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: July 16, 2021Publication date: January 13, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Publication number: 20220010010Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: July 16, 2021Publication date: January 13, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Patent number: 11111297Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: GrantFiled: November 15, 2018Date of Patent: September 7, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
-
Publication number: 20190153093Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: November 15, 2018Publication date: May 23, 2019Applicant: MERCK SHARP & DOHME CORP.Inventors: MICHAEL A. MEEHL, PHILIP E. BRANDISH, LAURENCE FAYADAT-DILMAN, VERONICA JUAN, CARL MIECZKOWSKI, LATIKA SINGH
-
Patent number: 9707276Abstract: Compositions and formulations comprising insulin or insulin analogs comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-118 to 145 of the beta subunit of human chorionic gonadotropin (hCG?) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analog is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogs are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogs comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans.Type: GrantFiled: November 22, 2013Date of Patent: July 18, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Michael Meehl, Richard D. DiMarchi, Pengyun Li
-
Publication number: 20160289290Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1-9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of NANA(1-4)Gal(1-4)GlcNAc(1-4)Man3GlcNAc2.Type: ApplicationFiled: January 14, 2016Publication date: October 6, 2016Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
-
Publication number: 20150374795Abstract: Compositions and formulations comprising insulin or insulin analogues comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-188 to 142 of the beta subunit of human chorionic gonadotropin (hCG?) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analogue is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogues are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogues comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans.Type: ApplicationFiled: November 22, 2013Publication date: December 31, 2015Applicants: MERCK SHARP & DOHME CORP., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Richard D. DiMarchi, Pengyun Li, Michael Meehl
-
Publication number: 20140235537Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1—9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1—4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(j.Type: ApplicationFiled: August 3, 2012Publication date: August 21, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
-
Publication number: 20140227290Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: ApplicationFiled: February 17, 2014Publication date: August 14, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Patent number: 8715963Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: GrantFiled: February 23, 2011Date of Patent: May 6, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Publication number: 20130011875Abstract: The present invention is related to methods and for producing higher titers of recombinant protein in a modified yeast host cell, for example Pichia pastoris, wherein the modified yeast cell lacks vacuolar sorting activity or has decreased vacuolar sorting activity relative to an unmodified yeast host cell of the same species. In particular embodiments vacuolar sorting activity is reduced or eliminated by deletion or disruption of a gene encoding Vps10 or a Vps10 homolog. The invention is also related to the modified yeast cells which are modified in accordance with the methods disclosed herein.Type: ApplicationFiled: October 25, 2010Publication date: January 10, 2013Applicant: Merck Sharpe & Dohme CorpInventors: Michael Meehl, Heping Lin, Byung-Kwon Choi
-
Publication number: 20120328626Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: ApplicationFiled: February 23, 2011Publication date: December 27, 2012Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Publication number: 20120213728Abstract: Compositions comprising granulocyte-colony stimulating factor (GCSF) produced in a strain of Pichia pastoris glycoengineered to produce a GCSF wherein greater than 18% of the molecules comprise an 0-glycan with one mannose per (0-glycan is described. In particular aspects, the GCSF is PEGylated at the JV-terminus.Type: ApplicationFiled: October 25, 2010Publication date: August 23, 2012Applicant: MERCKInventors: Michael Meehl, Sandra Rios, Sujatha Gomathinayagam, Huijuan Li, Piotr Bobrowicz